TLDR JFrog (FROG) dropped over 20% after Anthropic announced Claude Code Security, raising fears about AI disrupting traditional security tools. Raymond James keptTLDR JFrog (FROG) dropped over 20% after Anthropic announced Claude Code Security, raising fears about AI disrupting traditional security tools. Raymond James kept

JFrog (FROG) Stock Drops 20% After Anthropic’s Claude Code Security Launch

2026/02/22 01:27
4 min read

TLDR

  • JFrog (FROG) dropped over 20% after Anthropic announced Claude Code Security, raising fears about AI disrupting traditional security tools.
  • Raymond James kept its Outperform rating, calling the sell-off “excessive” and a potential buying opportunity.
  • JFrog beat Q4 estimates — EPS of $0.22 vs $0.19 expected, revenue of $145.31M vs $138.09M, up 25.2% year-over-year.
  • 19 analysts give FROG a consensus “Moderate Buy” with an average 12-month price target of $65.94.
  • Insiders sold roughly $24.97M worth of stock in the last 90 days, while the stock now trades around $37.75.

JFrog Ltd. (FROG) took a hard hit last week, falling more than 20% in a single session after Anthropic unveiled Claude Code Security — an AI-native tool that analyses vulnerabilities directly at the source-code layer.


FROG Stock Card
JFrog Ltd., FROG

Investors didn’t wait around to see how it plays out. The sell-off was swift and sharp.

The concern is straightforward: if AI can catch security issues during the coding process, do enterprises still need downstream package-level tools like JFrog’s Curation product? That question spooked the market.

There’s also a broader worry about perception. If companies start viewing AI-native security as “good enough,” they may slow adoption of JFrog’s incremental security modules. And longer-term, there’s fear Anthropic could expand into artifact scanning — territory that sits squarely in JFrog’s core business.

Despite all that, not everyone is running for the exit.

Raymond James maintained its Outperform rating on FROG, calling the sell-off “excessive.” The firm argues that the market is getting ahead of itself by extrapolating far beyond what Claude Code Security actually does right now.

Their case: JFrog operates at a different layer of the software stack — the artifact and package layer — where it provides policy enforcement and governance that large enterprises still need, regardless of what’s happening at the code review stage.

Q4 Results Were Actually Strong

It’s easy to forget, given the noise, that JFrog just posted a solid quarter.

The company reported Q4 EPS of $0.22, beating the consensus estimate of $0.19. Revenue came in at $145.31 million, ahead of the $138.09 million analysts expected — and up 25.2% compared to the same quarter last year.

For context, JFrog earned $0.19 EPS in Q4 of the prior year, so the year-over-year EPS improvement is real.

Looking ahead, the company set FY2026 EPS guidance at $0.88–$0.92 and Q1 2026 guidance at $0.20–$0.22 EPS. Full-year 2026 revenue is projected at $626 million by analysts, with Non-GAAP EPS of $0.90.

What Analysts Are Saying

The broader analyst community still leans positive. Of 19 brokerages covering the stock, 15 have a buy rating, three have a hold, and one has a sell. The average 12-month price target sits at $65.94 — well above the current trading price of $37.75.

Canaccord Genuity trimmed its target from $75 to $66 but kept its buy rating. TD Cowen went the other direction, raising its target from $75 to $80. UBS set a $60 target, while Cantor Fitzgerald reiterated an overweight rating with an $80 target. Wall Street Zen upgraded the stock from hold to buy on February 15th.

Raymond James points to JFrog’s security pipeline as a reason for confidence. Security accounted for 16% of Remaining Performance Obligations at the end of FY25, and analysts estimate that supports at least 50% year-over-year Security ARR growth for the current year.

On the insider front, executives and directors sold approximately $24.97 million worth of stock over the last 90 days. The stock currently trades at $37.75, within a 52-week range of $27.00 to $70.43.

Institutional investors hold 85.02% of FROG, with several new small positions initiated in Q4.

The post JFrog (FROG) Stock Drops 20% After Anthropic’s Claude Code Security Launch appeared first on CoinCentral.

Market Opportunity
Audiera Logo
Audiera Price(BEAT)
$0.24473
$0.24473$0.24473
+1.45%
USD
Audiera (BEAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03